⚠ Evidence warning: Clinical trials or other evidence do not support the claims that niranthin inhibits the hepatitis B virus polymerase at concentrations that matter in the body and escapes drug resistance, and that Phyllanthus lowers HBV-DNA in a meaningful minority, improves HBeAg seroconversion and clears HBsAg in 3-8% of people in modern trials. This page keeps it as a report of what people, websites or other media say.

Chanca Piedra for Hepatitis B: Niranthin Polymerase Inhibition, Clinical Trial Evidence, and Combination with Entecavir/Tenofovir

Liver Protection and Hepatitis B — scientific infographic poster

The companion Liver Protection page covers general hepatoprotection — the 1988 Thyagarajan Lancet headline, non-alcoholic fatty liver disease (NAFLD) signals, anti-tuberculosis hepatoprotection, drug interaction warnings. This page goes deeper on the one indication that drove Chanca Piedra into mainstream phytotherapy journals in the first place: chronic hepatitis B infection. We focus on the virology, the specific lignan that does the antiviral heavy lifting (niranthin), the surrogate-endpoint data from Phase II-style trials (HBsAg, HBeAg, HBV-DNA), how the herb's mechanism compares to nucleoside analogs like entecavir and tenofovir, and the honest answer to the question every hepatitis B virus (HBV) carrier eventually asks: "can I take this with my antiviral?"

Table of Contents

  1. Hepatitis B Virus Virology in 60 Seconds: Why HBsAg Loss Matters
  2. Niranthin: What the Cell and Duck Studies Measured
  3. Niranthin vs Nucleoside Analogs (Entecavir, Tenofovir, Lamivudine)
  4. HBsAg, HBeAg, and HBV-DNA Trial Data
  5. Dosing Used in the Trials
  6. Hepatitis C Virus and Other Chronic Hepatitides
  7. Alongside-Conventional-Therapy Strategy
  8. Monitoring Labs and What to Watch
  9. Limitations of the Evidence Base
  10. Situations Discussed and Who the Research Raises Concerns For
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Hepatitis B Virus Virology in 60 Seconds: Why HBsAg Loss Matters

Chronic hepatitis B virus (HBV) is a partially double-stranded DNA virus with a quirky replication cycle. After infecting a hepatocyte, the relaxed circular DNA (rcDNA) is converted in the nucleus into a stable, episomal covalently closed circular DNA (cccDNA) — the viral "minichromosome." cccDNA is the durable reservoir that makes hepatitis B virus a lifelong infection in most adults who acquire it.

From cccDNA, the virus transcribes a 3.5-kb pregenomic RNA (pgRNA), which is packaged into nucleocapsids along with the viral polymerase. The polymerase is a multifunctional enzyme: it acts as an RNA-dependent DNA polymerase (a reverse transcriptase) to copy pgRNA back into the partially double-stranded DNA genome, plus it has DNA-dependent DNA polymerase and RNase H activity. This reverse-transcriptase step is the Achilles' heel that all approved oral hepatitis B virus drugs target.

Serologic markers carry the clinical meaning:

This is why the original Thyagarajan paper made such a splash. It reported that 22 of 37 patients (59%) given a 30-day course had lost HBsAg when tested 15-20 days after treatment ended, against 1 of 23 (4%) on placebo. Modern entecavir and tenofovir, given for years, do not approach that. The Thyagarajan magnitude has never been independently reproduced — in the later carrier trials of Doshi 1994 and Wang 1995, and in a 2018 placebo-controlled trial, no patient lost HBsAg (details below). The biological plausibility of even the modest signal is what keeps the research going.

Back to Table of Contents

Niranthin: What the Cell and Duck Studies Measured

Of the four major aryltetralin lignans in P. amarus (phyllanthin, hypophyllanthin, niranthin, nirtetralin), niranthin is the standout antiviral. Mechanistic work over the past two decades has converged on several specific actions:

For the broader lignan/tannin profile see the Active Compounds page.

Back to Table of Contents

Niranthin vs Nucleoside Analogs (Entecavir, Tenofovir, Lamivudine)

It's worth being precise about how niranthin's mechanism differs from the approved drugs:

Because niranthin is not a nucleoside, some writers suggest it might still act on hepatitis B virus strains that resist nucleoside analogs (mutations such as rtM204V/I and rtL180M). This is a hypothesis: no study has tested niranthin against resistant strains, and there are no controlled trials of it. The idea that the two work differently is the basis for the combination logic discussed below.

The other side of the comparison — potency — is starkly in favor of the drugs. Entecavir has a cell-culture EC50 around 4 nM. Niranthin's half-maximal concentrations in the 2014 cell study were 15.6 µM and 25.1 µM — micromolar rather than nanomolar — although that study measured antigen release rather than the same endpoint. Niranthin is not going to replace entecavir for any patient who needs viral suppression. It might still contribute, which is the whole reason for the adjunctive-use literature.

Back to Table of Contents

HBsAg, HBeAg, and HBV-DNA Trial Data

The clinical literature on Phyllanthus in hepatitis B virus is uneven but not empty. The most-cited findings:

The pattern across the literature: the pooled reviews find more HBsAg, HBeAg and HBV-DNA clearance with Phyllanthus than with no treatment (Liu 2001) and with Phyllanthus added to an antiviral than with the antiviral alone (Xia 2011), but from mostly low-quality trials. The trials that tested carriers directly for HBsAg loss after Thyagarajan — Doshi 1994, Wang 1995 and the placebo-controlled Baiguera 2018 — found none. For comparison, HBsAg loss occurs in about 1% per year on entecavir/tenofovir. HBV-DNA does drop in a meaningful minority (typically 1-2 log10 reduction). HBeAg seroconversion is modestly improved (10-30% vs spontaneous rates of 5-15%). HBsAg loss is the headline endpoint that rarely reproduces at Thyagarajan magnitudes — usually 3-8% in modern trials, compared to ~1% per year on entecavir/tenofovir.

Back to Table of Contents

Dosing Used in the Trials

Dosing varies widely across the literature, which is one reason the meta-analyses are shaky. Representative protocols:

See Forms, Dosing & Standardization for the broader dosing matrix.

Back to Table of Contents

Hepatitis C Virus and Other Chronic Hepatitides

The hepatitis C virus (HCV) evidence base for Phyllanthus is much thinner than the hepatitis B virus record, and modern direct-acting antivirals (DAAs — sofosbuvir, glecaprevir, velpatasvir, etc.) cure hepatitis C virus in >95% of patients in 8-12 weeks. Phyllanthus has no comparable record of curing hepatitis C virus.

What the cell-culture and small-study literature suggests:

In short: the hepatitis C virus cure rates above come from DAAs. The Phyllanthus research on hepatitis C concerns liver protection after the cure, not antiviral action. For hepatitis B virus (where there is no cure, only suppression), the add-on antiviral question is the one most studied.

Back to Table of Contents

Alongside-Conventional-Therapy Strategy

For a chronic hepatitis B virus patient already on entecavir or tenofovir, what is the case for adding Chanca Piedra? The honest answer:

Back to Table of Contents

Monitoring Labs and What to Watch

Hepatitis B virus care already includes routine monitoring. The herb doesn't change what gets checked — it changes which changes matter.

Baseline (before starting):

3-month and 6-month reassessment:

Yearly:

Warning signs of liver injury or viral rebound: the changes below can come from a herb-related flare or from the virus returning. Jaundice, bleeding and falling liver function are signs of liver injury that hospitals treat as urgent.

Back to Table of Contents

Limitations of the Evidence Base

It's important to state the weaknesses of the Phyllanthus-HBV literature honestly:

Taken together, the Cochrane reviewers found "no convincing evidence that phyllanthus compared with placebo benefits patients with chronic HBV infection" (Xia 2011) and "insufficient evidence to support or refute the use of phyllanthus" against antiviral drugs (Xia 2013); the possible benefit they describe is as an add-on to an antiviral, with the quality problems above.

Back to Table of Contents

Situations Discussed and Who the Research Raises Concerns For

Situations in which Chanca Piedra is discussed as an add-on:

Situations in which the research raises concerns:

For any person with chronic hepatitis B virus, the largest danger is stopping the prescribed antiviral to switch to Chanca Piedra: NA discontinuation flares can be severe, up to acute liver failure. The AASLD and European Association for the Study of the Liver (EASL) guidelines set the criteria for when antivirals can be stopped.

Back to Table of Contents

Key Research Papers

  1. Thyagarajan SP, Subramanian S, Thirunalasundari T, Venkateswaran PS, Blumberg BS. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 1988;2(8614):764-6. — PubMed PMID: 2901611 · doi:10.1016/S0140-6736(88)92416-6
  2. Venkateswaran PS, Millman I, Blumberg BS. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA 1987;84(1):274-8. — PubMed PMID: 3467354 · doi:10.1073/pnas.84.1.274
  3. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database Syst Rev 2011;(4):CD008960. — PubMed PMID: 21491412 · doi:10.1002/14651858.CD008960.pub2
  4. Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat 2001;8(5):358-66. — PubMed PMID: 11555193 · doi:10.1046/j.1365-2893.2001.00307.x
  5. Shead A, Vickery K, Pajkos A, Medhurst R, Freiman J, Cossart Y. Effects of Phyllanthus plant extracts on duck hepatitis B virus in vitro and in vivo. Antiviral Res 1992;18(2):127-38. — Search PubMed · Search PubMed · doi:10.1016/0166-3542(92)90033-2
  6. Berk L, de Man RA, Schalm SW, Labadie RP, Heijtink RA. Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed. J Hepatol 1991;12(3):405-6. — PubMed PMID: 1940272 · doi:10.1016/0168-8278(91)90850-b
  7. Liu J, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B: a systematic review. Liver 2001;21(4):280-6. — Search PubMed · Search PubMed · doi:10.1034/j.1600-0676.2001.021004280.x
  8. Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus: ethnomedicinal uses, phytochemistry and pharmacology: a review. J Ethnopharmacol 2011;138(2):286-313. — PubMed PMID: 21982793 · doi:10.1016/j.jep.2011.09.040
  9. Calixto JB, Santos AR, Cechinel Filho V, Yunes RA. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 1998;18(4):225-58. — PubMed PMID: 9664291 · doi:10.1002/(sici)1098-1128(199807)18:4<225::aid-med2>3.0.co;2-x<225::aid-med2>3.0.co;2-x
  10. Wei W, Li X, Wang K, Zheng Z, Zhou M. Lignans with anti-hepatitis B virus activities from Phyllanthus niruri L. Phytother Res 2012;26(7):964-8. — Search PubMed · Search PubMed · doi:10.1002/ptr.3663
  11. Notka F, Meier GR, Wagner R. Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. Antiviral Res 2003;58(2):175-86. — Search PubMed · doi:10.1016/S0166-3542(02)00213-9
  12. Lam WY, Leung KT, Law PT, et al. Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. J Cell Biochem 2006;97(4):795-812. — Search PubMed · Search PubMed · doi:10.1002/jcb.20611
  13. Doshi JC, Vaidya AB, Antarkar DS, Deolalikar R, Antani DH. A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen. Indian J Gastroenterol 1994;13(1):7-8. — PubMed PMID: 8119752
  14. Wang M, Cheng H, Li Y, Meng L, Zhao G, Mai K. Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. J Lab Clin Med 1995;126(4):350-2. — PubMed PMID: 7561442
  15. Liu S, Wei W, Shi K, Cao X, Zhou M, Liu Z. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L. J Ethnopharmacol 2014;155(2):1061-7. — PubMed PMID: 25009077 · doi:10.1016/j.jep.2014.05.064
  16. Baiguera C, Boschetti A, Raffetti E, Zanini B, Puoti M, Donato F. Phyllanthus niruri versus placebo for chronic hepatitis B virus infection: a randomized controlled trial. Complement Med Res 2018;25(6):376-382. — PubMed PMID: 30372693 · doi:10.1159/000484927
  17. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database Syst Rev 2013;(4):CD009004. — PubMed PMID: 23633363 · doi:10.1002/14651858.CD009004.pub2
  18. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020;73(3):523-532. — PubMed PMID: 32335166 · doi:10.1016/j.jhep.2020.04.008
  19. Wedemeyer H, Aleman S, Blank A, et al. 144 weeks of bulevirtide monotherapy for chronic hepatitis D: final and post-treatment results from a phase III randomized trial. J Hepatol 2026;85(3):493-503. — PubMed PMID: 41966308 · doi:10.1016/j.jhep.2026.03.046

PubMed Topic Searches

  1. PubMed: niranthin HBV polymerase
  2. PubMed: P. amarus HBsAg loss
  3. PubMed: Phyllanthus + entecavir
  4. PubMed: Phyllanthus + tenofovir
  5. PubMed: HBeAg seroconversion
  6. PubMed: Phyllanthus & HCV
  7. PubMed: Phyllanthus & cccDNA
  8. PubMed: reverse transcriptase

Back to Table of Contents

Connections

Back to Table of Contents